Cargando…
Efficacy and Safety of 3‐Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases
Autores principales: | Arase, Yoshitaka, Tsuruya, Kota, Hirose, Shunji, Ogiwara, Naoki, Yokota, Masashi, Anzai, Kazuya, Deguchi, Ryuzo, Shiraishi, Koichi, Shirai, Takayuki, Kagawa, Tatehiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028030/ https://www.ncbi.nlm.nih.gov/pubmed/31429969 http://dx.doi.org/10.1002/hep.30904 |
Ejemplares similares
-
First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023) -
Loss of organic anion transporting polypeptide 1B3 function causes marked delay in indocyanine green clearance without any clinical symptoms
por: Kagawa, Tatehiro, et al.
Publicado: (2017) -
Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018) -
Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Arase, Yoshitaka, et al.
Publicado: (2019) -
Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B
por: Nagata, Naruhiko, et al.
Publicado: (2016)